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Abstract: Given the rise of apoptosis-resistant tumors, exists a growing interest in 
developing new drugs capable of inducing different types of cell death 
to reduce colorectal cancer-related death rates. As apoptosis and necroptosis do not 
share cellular machinery, necroptosis induction may have a great therapeutic potential 
on those apoptosis-resistant cancers, despite the inflammatory effects associated with it. 
We have synthesized an alkynyl gold(I) complex [Au(C≡C-2-NC5H4)(PTA)] whose 
anticancer effect was tested on the colorectal adenocarcinoma Caco-2 cell line. With 
regard to its mechanism of action, this gold complex enters the mitochondria and 
disrupts its normal function, leading to an increase in ROS production, which triggers 
necroptosis. Necroptosis induction has been found dependent of TNF-α and TNFR1 
binding, RIP1 activation and NF-κB signaling. Moreover, the antitumor potential of 
[Au(C≡C-2-NC5H4)(PTA)] has also been confirmed on the 3D cancer model spheroid. 
Overall, the obtained data show firstly that gold complexes might have the ability of 
inducing necroptosis, and secondarily that our compound [Au(C≡C-2-NC5H4)(PTA)] is 
an interesting alternative to current chemotherapy drugs in cases of apoptosis resistance.  
KEYWORDS Gold complex, cancer, necroptosis, ROS, Caco-2 cells 
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INTRODUCTION 
The use of metals with therapeutic purposes dates back to ancient times. Nevertheless 
one of the biggest successes for inorganic chemistry in medicine was the accidental 
discovery of antitumor properties of cisplatin in the 60s. cis-[PtCl2(NH3)2], commonly 
called cisplatin has been used worldwide in chemotherapy against various cancers 
including testicular, ovarian and solid tumors of head and neck [1,2].  However, the use 
of platinum derivatives results in serious side effects related to their nonspecific 
mechanism of action [3]. Thus, in the last decades researchers have focused on finding 
new metal derivatives with anticancer properties that lack the shortcomings of cisplatin 
and its analogues.   
In this context, gold complexes are an interesting alternative to platinum-containing 
drugs [1,2]. Many gold(I) complexes have been tested against various tumor cell lines, 
[4-6] and some of these promising in vitro results have also been confirmed in vivo 
using animal models [4,7,8]. The main advantage of these compounds against platinum 
complexes is that they differ in their mechanism of action. Whereas platinum 
compounds interact with nucleic acids, gold-containing drugs display a higher variety of 
targets, including non-canonical DNA structures [9, 10], zinc finger proteins [11] or the 
redox enzyme thioredoxin reductase (TrxR).  Gold complexes are able to inhibit TrxR 
via interacting with the selenium atom [12]
 
of the selenocysteine moiety. When TrxR is 
inhibited, the regular redox balance becomes disrupted and the abnormally increased 
levels of reactive oxygen species (ROS) trigger cell death [13].
 
Consequently, TrxR 
inhibition does not involve the side effects related to treatment with cisplatin and its 
analogues. In addition, there is not cross-resistance between them [14]. Therefore, gold-
containing drugs are able to induce cell death even in cisplatin-resistant cancer cells.  
Colorectal cancer (CRC) is one of the most prevalent cancers in Western countries and 
one of the main causes of cancer-related death [15]. CRC is a kind of tumors which 
shows a good response to treatment with metallic compounds, since the combination of 
the cisplatin analogue oxaliplatin (cis-[oxalate(trans-l-1,2-
diaminocyclohexane)platinum(II)]) and traditional chemotherapy improves patient 
response versus traditional chemotherapy alone [16,17]. Consequently, it is necessary to 
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find new therapeutic options with fewer side effects than current treatments but 
maintaining their anticancer potential.  
Treatment with metallic compounds usually induces apoptosis, one of the best 
characterized kinds of cell death [18, 19]. As an example, we have recently described in 
detail the apoptotic insights of an alkynyl gold(I) complex [20]. But, given the rise of 
apoptosis-resistant tumors exist a growing interest in developing new drugs capable of 
inducing different types of cell death [21]. 
Necroptosis is a regulated form of necrosis mainly governed by Receptor-Interacting 
Protein 1 (RIP1), RIP3 and Mixed Lineage Kinase Domain-Like (MLKL) protein. A 
wide range of stimuli can start this process, although the best studied pathway is 
triggered by Tumor Necrosis Factor (TNF). TNF-triggered necroptosis requires the 
formation of “necrosome”, a protein complex in which RIP1 and RIP3 are involved and 
responsible for MLKL phosphorylation. The necrosome migrates to plasma membrane 
and induces its rupture, [22, 23] so it is the ultimate responsible for necroptotic 
morphological features, i.e. cellular swelling and loss of intracellular content. Therefore, 
as apoptosis and necroptosis do not share the same molecular pathways, necroptosis-
inducing drugs may induce cell death on apoptosis-resistant tumors.   
2D cell culture provides only a slanted vision of how cells behave inside human body; 
therefore, results in 2D cannot always be translated into in vivo settings. To obtain more 
accurate information about cell response to that observed in vivo, 3D cell cultures have 
proved an useful alternative [24]. 3D cell models provide a more relevant 
microenvironment where cell-cell and cell-matrix interactions are promoted. 
Particularly, cells acquire relevant features observed in tumors in vivo, such as 
distinctive morphological and cellular characteristics, as well as distinctive gene 
expression signature, which could account for the different drug response to that 
observed in 2D [25, 26]. Among the 3D cell culture methods, spheroids are one of the 
best characterized models so far. They closely recapitulate the tumor microenvironment, 
including hypoxia and metabolic gradients. Furthermore, previous studies in spheroids 
have provided insight on drug distribution and penetration. [27, 28]. All in all, cell 
spheroids are a 3D cell culture method usually used in drug-response studies [29, 30]. 
Specifically, Caco-2 spheroids have been previously used in permeability assays as the 
obtained values were quite similar to those found in vivo [31]. 
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Here we describe the preparation and evaluation of the anticancer activity of the 
alkynyl gold(I) derivative [Au(C≡C-2-NC5H4)(PTA)] (Chart Scheme 1) against human 
colon cancer cells (Caco-2). We have established its ability to induce necroptosis by 
increasing ROS levels, which triggers cell death. Due to the spontaneous differentiation 
of Caco-2 cells to normal enterocytes after 15 days growing [32], we were able to 
compare its effect on both CRC and healthy tissue. Additionally, data obtained in 2D 
cell model were expanded by testing the antiproliferative effect of the compound on 3D 
spheroid model.   
N
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Scheme 1. Chemical structure of [Au(C≡C-2-NC5H4)(PTA)]. 
MATERIALS AND METHODS 
Preparation of [Au(C≡C-2-NC5H4)(PTA)]. The alkynyl gold complex was prepared 
as described previously by some of us [33]. Pale yellow solid was isolated in 78% yield. 
1
H NMR (400 MHz, CDCl3, 25 °C): δ = 4.37 and 4.51 (AB system, 6H, NCH2N), 4.33 
(s, 6H, NCH2P), 7.01 (dd, J = 4.8/1.5Hz, 1H, NC5H4 (H
5
)), 7.3 (d J = 7.8, NC5H4 (H
3
)),
7.48 (td, J = 7.6/1.5Hz, 1H, NC5H4 (H
4
)), 8.42 (d, J = 4.8Hz, 1H, NC5H4 (H
6
)) ppm.
 
31
P{
1
H} NMR (162 MHz, CDCl3, 25 °C):  = –51.8 ppm. 
13
C{
1
H} NMR (75.4 MHz,
CDCl3, 25 °C):  = 51.1 (d, J = 16 Hz, NCH2P), 68.4 (s, AuCC), 72.2 (s, NCH2N), 
85.1 (s, AuCC), 121.8 (s, C5,3-Py), 130,7 (s, C4-Py), 150.3 (s, C6-Py). IR (KBr): 2105
cm
-1
 (CC). FAB MS: m/z = 457 [M]+. Elemental analysis calcd. (%) for
C13H16AuN4P (456.23): C 34.22, H 3.53, N 12.28; found: C 34.55, H 3.75, N 12.50. 
Chemical stability. The stability of the gold complex was analyzed by absorption UV 
spectroscopy. UV-Vis absorption spectra were recorded on a Thermo Scientific 
spectrophotometer. 10 mM solution of [Au(C≡C-2-NC5H4)(PTA)] in DMSO was 
diluted in 10
-4 
M PBS pH = 7.4 and thereafter monitored by measuring the electronic
spectra over 24 h at 37°C. Additionally, a phosphate-buffered saline solution, pH 7.4 
was added to a d6-DMSO solution of the complex in a proportion 1:1 (due to the low 
solubility in water solution) and studied by NMR over 24h period. 
ACCEPTED MANUSCRIPT
5 
Distribution coefficient (logD7.4). The n-octanol-water partition coefficient of 
[Au(C≡C-2-NC5H4)(PTA)] was determined as previously reported using a shake-flask 
method [33]. The concentration of the compound in each phase was determined using 
UV absorbance spectroscopy. LogD7.4 was defined as 
log{[compound(organic)]/[compound(aqueous)]}. 
Interaction with BSA. Interaction of gold complex and bovine serum albumin 
(purchased from Sigma Aldrich) was analyzed as previously described by some of us 
[20]. 
DNA binding studies. Interaction of gold complex with DNA was studied using 3 
nM pIRES2-EGFP plasmid (Clontech). Gold complex was diluted in miliQ water and 
different ratio of gold complex toplasmid were incubated 24 h at 37ºC. Electrophoretic 
mobility shift assays were performed by PAGE electrophoresis (90 min, 50 V) in TBE 
buffer using SYBR Safe as stain.  
Cell culture. Human Caco-2 cell line (TC7 clone) was kindly provided by Dr. Edith 
Brot-Laroche (Université Pierre et Marie Curie-Paris 6, UMR S 872, Les Cordeliers, 
France). Caco-2 cells were maintained in a humidified atmosphere of 5% CO2 at 37ºC. 
Cells (passages 50-80) were grown in Dulbecco’s Modified Eagles medium (DMEM) 
(Gibco Invitrogen, Paisley, UK) supplemented with 20% fetal bovine serum (FBS), 1% 
non-essential amino acids, 1% penicillin (1000 U/mL), 1% streptomycin (1000 μg/mL) 
and 1% amphoterycin (250 U/mL). The cells were passaged enzymatically with 0.25% 
trypsin-1 mM EDTA and sub-cultured on 25 or 75 cm
2
 plastic flasks at a density of
2·10
4
 cells/cm
2
. Culture medium was replaced every 2 days. Cell confluence (80%) -
considered as differentiated cells- was confirmed by microscopic observance. 
Experiments in undifferentiated cells were performed 24 hours post-seeding. 
Human MCF-7 cell line was kindly provided by Dr. Carlos J. Ciudad y Dra. Verònica 
Noé (Departamento de Bioquímica y Fisiología, Facultad de Farmacia, Universidad de 
Barcelona, Spain). MCF-7 cells were maintained in the same conditions as described for 
Caco-2 cell line.  
Cell proliferation assay and IC50 value determination. Cell proliferation inhibition 
was measured using the MTT assay [34]. Caco-2/TC7 cells were plated in 96-well 
plates at a density of 4000 cells/well and incubated for 24 h under standard cell culture 
conditions. For IC50 values determination, a stock solution of the gold complex in 
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dimethyl sulfoxide (DMSO) was added to cells in a concentration range of 0-20 μM (10 
replicates, 100 µL per well); cells treated with the same amount DMSO were used as 
negative control. Cells were exposed to the gold complex for 24 h and then 10 µL of 
MTT (5 mg/ml) was added. Incubation was continued at 37ºC for 3 h. Medium was then 
removed by inversion and 100 µL of DMSO/well were added. Absorbance at 560 nm -
proportional to number of live cells- was measured by spectrophotometry (DTX 800, 
Beckman Coulter) and converted into percentage of growth inhibition.  
Thioredoxin reductase activity assay in cells. Caco-2/TC7 were grown in 96-well 
plate at a density of 4.000 cells/well during 24h, and then treated with [Au(C≡C-2-
NC5H4)(PTA)] for 24 h. After the incubation, cells were lysed with lysis buffer (50 mM 
Tris-HCl pH 7.5, 2 mM EDTA, protease inhibitor cocktail and distilled H2O) for 30 min 
at room temperature. Then, TrxR inhibitor was added to each well and incubated 30 
min. Cell lysates were incubated with reaction buffer (PBS pH 7, 100 mM EDTA, 
0.05% BSA, 20 mM NADPH, distilled H2O) with or without TrxR inhibitor. Reaction 
was started by adding 25 µL of 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB, 20mM in 
pure ethanol). Absorbance at 405nm was recorded every 10s for 6min as a measurement 
of thioredoxin reductase activity. TrxR activity was normalized by the amount of 
protein present in each well, determined by Bradford method. 
Glutathione activity assay in cells. Caco-2/TC7 were grown in 96-well plate at a 
density of 4.000 cells/well during 24h, and then treated with [Au(C≡C-2-NC5H4)(PTA)] 
for 24 h. After the incubation, cells were lysed with modified RIPA buffer (50 mM Tris-
HCl, 50 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% SDS, 1% DOC, 1 mM NaF, in 
miliQ water) with proteases inhibitors. Cell solution was shaken at RT for 20min, 
centrifuged for 5 min at 1200 rpm and resuspended in PBS. Then, reaction solution was 
added (0.1 M Tris-HCl pH 8.1, 0.02 mM NADPH, in PBS). Finally, reaction was 
started by adding 0.52 mM GSSG. Absorbance at 3340 nm was recorded for 6 min. 
Glutathione reductase activity of the cell lysate was measured as a loss in absorbance at 
340 nm. 
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Measurements of apoptosis. Caco-2/TC7 cells were exposed to IC50 of [Au(C≡C-2-
NC5H4)(PTA)] for 24 h, then collected and stained with Annexin V-FITC as described 
by Sánchez-de-Diego et al [20]. Untreated cells were used as negative control, in order 
to define basal levels of apoptosis, necrosis and cell death.  
Propidium iodide staining of DNA content and cell cycle analysis. Caco-2/TC7 
cells were exposed to IC50 of [Au(C≡C-2-NC5H4)(PTA)] for 24 h and then DNA 
content was analyzed as described by Sánchez-de-Diego et al [20].  
Caspase activity studies. Caspase activation was studied using CellEvent
TM 
Caspase-
3/7detection reagent (C10423, ThermoFisher). Caco-2/TC7 cells were plated in 96-well 
plates at a density of 4000 cells per well and incubated for 24 h under standard cell 
culture conditions. For treatment, IC50 of [Au(C≡C-2-NC5H4)(PTA)] was added to cells 
and incubated 24 h; mock-treated cells were incubated with DMSO. Then, medium was 
removed and the reagent, previously diluted in PBS (90 µL /mL), was added to the 
cells. After 10 min of incubation, fluorescence was observed using confocal microscopy 
in a Nikon Eclipse Ti
®
 inverted fluorescence microscope, coupled with a confocal
module. Excitation and emission settings were 488 and 590/50 nm respectively. The 
intensity of fluorescence was analyzed with Fiji software (http://fiji.sc/Fiji).  
Measurement of total cellular oxidative stress. Caco-2/TC7 cells were exposed to 
IC50 of [Au(C≡C-2-NC5H4)(PTA)] for 80 min and then CellROX
®
 Deep Red Reagent
(C10422, ThermoFisher) was added to a final concentration of 5 µM. Cells were 
incubated 30 min at 37ºC. Fluorescence was analyzed using confocal microscopy in a 
Nikon Eclipse Ti® inverted fluorescence microscope, coupled with a confocal module. 
Excitation and emission settings were 644 and 665 nm, respectively. The intensity of 
fluorescence was analyzed with Fiji software (http://fiji.sc/Fiji) and is considered a 
reflection of total intracellular ROS.  
Determination of H2O2 cellular levels. H2O2 production was assessed using the 
dichlorofluorescein (DCF) assay [35]. Caco-2/TC7 cells were plated in 96-well plates at 
a density of 4000 cells per well and incubated for 24 h under standard cell culture 
conditions. For treatment, IC50 of [Au(C≡C-2-NC5H4)(PTA)] was added to cells and 
incubated 80 min; mock-treated cells were incubated with DMSO. Determination of 
H2O2 cellular levels was performed as described by Sánchez-de-Diego et al.  [20]. 
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Flow cytometry mitochondrial membrane potential assay. Caco-2/TC7 cells were 
plated in 75 cm
2
 flasks at a density of 500.000 cells per flask and incubated 24 h under
standard cell culture conditions. For treatment, IC50 of gold complex was added to each 
flask and incubated 24 h; mock-treated cells were incubated with DMSO. After 
treatment, changes in Δψm were analyzed as described by Sánchez-de-Diego et al [20]. 
Determination of RIP1 by flow cytometry. Caco-2/TC7 cells were plated in 75 cm
2
flasks at a density of 500.000 cells per flask and incubated 24 h under standard cell 
culture conditions. For treatment, IC50 of gold complex was added to each flask and 
incubated 24 h; mock-treated cells were incubated with DMSO. After treatment, cells 
were harvested and 100 µL of fixation solution INTRACELL (Intra 100-T, 
Immunostep) were added to each 50 µL of cells. Mix was incubated 5 min at room 
temperature and then was washed with PBS. Cells were resuspended in 50 µL PBS and 
100 µL of permeabilisation solution INTRACELL (Intra 100-T, Immunostep) and 3 µL 
anti-RIP-1 antibody (Abcam ab72139, 1/100 dilution) were added. After 1 h incubation 
at 4ºC, cells were washed with 1 mL PBS and 50 µL of permeabilisation solution 
INTRACELL (Intra 100-T, Immunostep) were added. Finally, secondary antibody goat 
anti-mouse ALEXA 488 was added and samples were incubated 30 min at 4ºC. Cells 
were washed and resuspended in 200 µL PBS and fluorescence was analyzed by flow 
cytometry using a FACSARRAY BD equipped with an argon ion laser. 
Caco-2 spheroids generation. Caco-2 cells (3·10
3
 cells per plate) were mixed with a
high viscosity methylcellulose solution as described by Ayuso et al [36] and 100 µL of 
the final suspension were seeded on a round bottom 96-well plate. Spheroids were 
grown for 72 h and were then incubated with rising concentrations of [Au(C≡C-2-
NC5H4)(PTA)] (3, 4 and 5 μM) for 24 h. For cell viability studies, spheroids were 
stained with Hoechst 33342 (4 mg/mL) and PI (4 mg/mL) for 30 min. Then, confocal 
microscopy images were taken as previously described.  
RESULTS AND DISCUSSION 
Solution chemistry. The alkynyl derivative [Au(C≡C-2-NC5H4)(PTA)] (1) was isolated 
as an stable light yellow solid in high yield. Its behavior in solution was analyzed by 
absorption spectroscopy and NMR. A phosphate-buffered saline (PBS) solution of the 
complex was incubated at 37ºC and studied by UV-visible spectroscopy over 24h. The 
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spectrum displays two intense bands around 215 and 290 nm and another band with 
lower intensity at 250 nm, attributed to electronic transitions from the alkyne ligand to 
the gold(I) center (Figure S2). These bands decrease their intensity over the time and a 
slight blue shift of the band at 290 nm is observed after 5h of incubation. Non-
additional bands were observed during the experiment course and, more importantly, no 
new bands in the region of 500 nm, characteristic of colloidal gold(0) were detected. In 
addition, the NMR spectra in a mixture of PBS and d6-DMSO solution revealed no 
decomposition and no release of the phosphane after 24h period (Figure S3). With these 
results, this complex can be considered sufficiently stable in the solution to be tested on 
cells. 
The lipophilicity of a compound is associated to its diffusion and penetration into the 
cell membrane. Consequently, drug lipophilicity affects its activity, toxicity to healthy 
tissues and is directly related to plasma protein binding and metabolism of the drug 
[37]. Changes in drug lipophilicity by incorporating the suitable functional groups in the 
molecule have shown great impact in anticancer activity and host toxicity [38, 39]. 
However, phosphane gold(I) derivatives with high lipophilicity [39] tend to accumulate 
into mitochondria with the consequent serious effects [40]. Subsequently, a balanced 
relationship between lipophilicity and hydrophilicity would be highly desirable. 
Lipophilicity can be measured by the partition coefficient water/octanol, logD7.4, which 
finally shows the corresponding balance between lipophilicity and hydrophilicity. The 
measurement of logD7.4 of our alkynyl derivative (see experimental for details) gave a 
negative value next to 0 (-0.10). This is in accordance with slight hydrophilic character 
of the complex, albeit with a balanced relationship between both characters. 
Binding to BSA. The distribution, free concentration and metabolism of a drug are 
affected by drug-protein interactions in the bloodstream [41, 42]. Such interaction can 
influence drug stability and toxicity during chemotherapeutic treatment, thereafter 
limiting drug efficacy. Consequently, it is important to understand the potential 
presence and nature of these interactions. One of the blood plasma proteins involved in 
drug transport is serum albumin. Bovine serum albumin (BSA) is frequently used in 
biochemical analysis due to its higher stability and accessibility. BSA contains two 
tryptophan residues (Trp-134 and Trp-212) in the former while HAS (human serum 
albumin) has a unique tryptophan. Hence, we have studied the interaction of [Au(C≡C-
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2-NC5H4)(PTA)] with BSA by means of the measurement of the quenching of the 
intrinsic fluorescence of the amino acid tryptophan, which is sensitive to its local 
environment. Accordingly, any changes in the fluorescence emission spectra can be 
attributable to changes in the conformation, due to the presence of the quencher [43]. 
The fluorescence spectra of BSA were recorded in the presence of increasing amounts 
of the gold complex in the range of 310-450nm upon excitation at 295 nm. Quenching 
of the fluorescence is observed in a concentration dependent manner, without changes 
in the emission maximum and shape of the peaks (Figure 1A). This fact points to an 
interaction of the gold complex with the protein without alteration of the vicinity of the 
tryptophan residues.  
The quenching process can be due to the presence of collisions between a fluorophore 
with the quenching agent ˗dynamic quenching˗ or the formation of a non-fluorescent 
complex with the quenching agent, i.e. static quenching. Fluorescence data were 
analyzed by the Stern-Volmer equation: F0/F = 1+ Ksv[1], where F0 and F are the steady 
sate fluorescence intensities of BSA before and after the addition of the gold complex. 
While a linear Stern-Volmer plot (F0/F vs. [quencher]) is indicative of the occurrence of 
a single quenching mechanism, the plot F0/F vs with a positive deviation (Figure 1B) 
suggests the presence of a combination or static and dynamic quenching. Moreover, the 
upward curvature in the plot indicates that both tryptophan residues in the BSA 
molecule are exposed to the gold complex [44]. 
The modified Stern-Volmer equation:   
      
 
             provides the 
corresponding binding constant Kb, by using the plot of log(F0-F)/F vs log[1],  (Figure 
1C). The binding constant was found to be 2.3·10
8
 M
-1
, which indicates a high affinity
of our complex to the protein, and inversely decreases with the temperature. This high 
value points to a strong interaction between BSA and the gold complex. The value of Kb 
of 2.46·10
8
 increased four orders of magnitude in comparison to the related complex,
with a phenyl ring instead of the pyridine molecule [Au(C≡C-C5H4)(PTA)] (Kb of 
7.2·10
4
 M
-1
)[41]. In order to calculate the nature of the binding sites between [Au(C≡C-
2-NC5H4)(PTA)] and BSA, we have performed the quenching experiment at different 
temperatures (295, 304 and 310K). Values of n next to 2 indicate that there is more than 
one class of binding site in the interaction of the gold complex towards BSA.  
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Considering that we performed the quenching study at three temperatures, we can only 
approximate the corresponding thermodynamic parameters Hº, Sº and Gº, which 
have been calculated from the equation lnK = -Hº/(RT) + Sº/R, where K is the 
equilibrium constant at the three different temperatures, Hº and Sº are the standard 
enthalpy and entropy change for the reaction, respectively and R, the gas constant 8.314 
J·mol
-1
K
-1
. The calculated values for the experiment Hº and Sº provide Gº < 0
(Table 1, Figure S8)). 
The interaction forces of biomolecules and drugs involve hydrophobic forces, 
electrostatic interactions, van der Waals interactions or hydrogen bonds [45]. The 
negative value calculated for Gº is indicative of a spontaneous process and the 
negative values for both enthalpy and entropy of the interaction are consistent with the 
presence of van der Waals interaction and hydrogen bonds [45]. 
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In addition, we have measured the UV-visible absorption spectra of the BSA in 
presence and in absence of the gold complex (figure S13). The absorption spectrum of 
Table 1. Thermodynamic parameters of [Au(C≡C-2-NC5H4)(PTA)]-BSA interaction. 
T (K) Kb (M
-1
) n Hº (kJ·mol-1) Sº (J·mol-1K-1) Gº (kJ·mol-1)
295 2.46·10
8 1.70 
-78.78 -105.9 
-47.54 
304 8.98·10
7
1.62 -46.58 
310 5.95·10
7
1.60 -45.95 
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Figure 1. A) Fluorescence quenching of BSA in presence of increasing concentrations of [Au(C≡C-
2-NC5H4)(PTA)] (1) at 295 K. Arrow indicates the increase of the quencher concentration. B) 
Stern-Volmer plot for the quenching of BSA with 1 at 295K. Stern-Volmer equation used: F0/F = 1 
+ Ksv[1]. C) Stern-Volmer equation used: log{(F0-F)/F} = logKb + nlog[1]. The intercept of the best 
fit linear trend provides the Stern-Volmer quenching constant Kb. 
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protein is only influences by complexation with quencher in ground state (static 
process). In our case a hyperchromism is observed after addition of the complex, which 
is in accordance with alteration in the microenvironment around the aromatic acid 
residues, whereas the presence of hypochromism is associated to an induced 
perturbation of -helix of the protein with the quencher [46].   
[Au(C≡C-2-NC5H4)(PTA)] antiproliferative activity. The in vitro effects of 
[Au(C≡C-2-NC5H4)(PTA)] toward human colon (Caco-2/TC7) and breast cancer 
(MCF-7) cell lines were tested using the colorimetric MTT assay. Firstly, we obtained 
the IC50 value after exposing cells to increasing drug amounts for 72 h (Table 2). Caco-
2 cell line typically undergo enterocyte-like differentiation after reaching confluence, 
becoming polarized cell that expresses apical and basolateral surfaces with well-
established tight junctions [30].
 
Consequently, it is possible to test the selectivity of the 
gold complex by testing its effects on differentiated cells (non-carcinogenic) in terms of 
viability. Undifferentiated Caco-2/TC7 cells showed higher sensibility to treatment 
compared with human breast cancer MCF-7 cells, with an IC50 value of 5-fold lower. 
These results suggest that therapeutic effect of [Au(C≡C-2-NC5H4)(PTA)] may be 
selective to colorectal cancer. On the other hand, [Au(C≡C-2-NC5H4)(PTA)] displayed 
a higher IC50 -up to 13-fold- on differentiated Caco-2 cells compared  to the previously 
obtained on  undifferentiated cells. Therefore, our compound might be selective to 
cancer tissue.  
Finally, some of us have previously evaluated the antiproliferative effect of the 
reference drug cisplatin in Caco-2 cell line, obtaining an IC50 value of 45.6 ± 8.08 µM 
[47]. In conclusion, [Au(C≡C-2-NC5H4)(PTA)] shows higher cytotoxicity than 
cisplatin.  
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In addition, further assays revealed that [Au(C≡C-2-NC5H4)(PTA)] antiproliferative 
effects on Caco-2 increased in a dose and time-dependent manner (Figure 2). 
Cell death studies. Previous studies on the alkynyl gold(I) derivative 
[Au(C≡CPh)(PTA)] revealed strong induction of intrinsic apoptosis on undifferentiated 
Caco-2/TC7 cells [20]. In consequence, we firstly assumed related cell death by 
apoptosis and performed flow cytometry analysis of annexin V/propidium iodide-
stained Caco-2/TC7 cells.  
Figure 2. Survival curves of Caco-2 cells treated with increasing concentrations of [Au(C≡C-2-
NC5H4)(PTA)]  (0, 1, 3, 5, 7, 10 and 15 µM) at 24 (squares) or 72 h (circles).  
Table 2. Antiproliferative IC50 values 
of [Au(C≡C-2-NC5H4)(PTA)]. 
Cell line IC50 value 
Differentiated 
Caco-2/TC7 
51.04± 1.28 µM 
Undifferentiated 
Caco-2/TC7 
3.8 ± 1.1 µM 
MCF-7 19.02 ± 0.02 µM 
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After 24 h incubation with [Au(C≡C-2-NC5H4)(PTA)] we only observed a slight 
increase in late apoptotic levels (among 1.7-fold) (Table 3). These analyses also 
revealed a decrease in cell number after treatment with our gold compound (between 
two and three times), confirmed by Trypan blue exclusion test (Supplementary Material, 
Table T1). 
Then we investigated two common apoptotic features: cell cycle arrest [48] (Figure 3.1) 
and caspases 3 and 7 activation [18] (Figure 3.2). No significant differences were 
observed in comparison with mock-treated cells in both cases. Moreover, nuclear 
staining with Hoechst 33342 revealed changes in nuclear morphology after treatment 
with [Au(C≡C-2-NC5H4)(PTA)] (Figure 3.2), showing a clear swelling that is not a 
typical apoptotic feature [18,19]. The absence of apoptotic biomarkers in addition to the 
statements of Pietkiewicz et al [49] ˗it is impossible to distinguish between late 
apoptotic and necroptotic cells by using the classical double staining annexin V-PI˗ 
were evidences of a different type of cell death induction than apoptosis. Thus, we 
investigated necroptosis induction.  
Table 3. Percentages of Caco-2/TC7 cells undergoing cell death analyzed with double stain Annexin 
V and propidium iodide. 
Treatment Total 
events 
Alive 
(%) 
Necrosis 
(%) 
Early apoptosis 
(%) 
Late apoptosis 
(%) 
Mock-treated 2408 75.6 0.9 15.3 8.2 
[Au(C≡C-2-NC5H4)(PTA)] 1456 62.3 0.5 22.9 14.3 
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Figure 3.1 Cell cycle analysis. Percentages of cells undergoing each phase are showed. 
Figure 3.2 Double staining with Hoechst 33342 and CellEvent Caspase-3/7 Green detection reagent after 24 h 
treatment with A) DMSO or B) [Au(C≡C-2-NC5H4)(PTA)], (3.8 µM). Nuclei swelling are also highlighted (white 
arrows). 
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[Au(C≡C-2-NC5H4)(PTA)] does not bind DNA. We evaluated the possible 
interaction of this alkynyl derivative with DNA by monitoring its influence on pIRES2-
EGFP (5308 pb) plasmid DNA by agarose gel electrophoresis in comparison to 
cisplatin. Figure S10 displays that mobility of the plasmid is not affected after 
incubation with increasing amounts of our gold derivative, unlike the variation observed 
with the reference drug. This lack of DNA interaction is shared with auranofin and other 
gold(I) derivatives [20,50]. 
[Au(C≡C-2-NC5H4)(PTA)] triggers necroptosis via ROS generation. The best 
characterized form of necroptosis is the one triggered by the cytokine Tumor Necrosis 
Factor-alpha (TNF-α). In TNF-α-triggered necroptosis, TNF receptor 1 (TNFR1) is 
stimulated by TNF binding and, as a consequence of its activation, recruits different 
proteins including RIP-1 in order to form a transient protein complex. Once in this 
complex, RIP-1 is ubiquitinated, necessary for NF-κB activation and the final 
consecution of necroptosis [51]. Given the importance of these three proteins for 
necroptosis induction, we investigated the effect of their inhibition on [Au(C≡C-2-
NC5H4)(PTA)]-triggered cell death. Co-incubation of Caco-2 cells with our gold 
complex and the RIP-1 inhibitor necrostatin-1 (Nec-1) (50 µM, 1 h pre-incubation; 
Figure 4.A), a TNFR1 analog (2 μM, 1 h pre-incubation; Figure 5A) and the NF-κB 
inhibitor SN50 (1 μM, 1 h pre-incubation; Figure 5B) conducted to an increased 
survival ratio. Moreover, flow cytometry analysis revealed an increase of 8.5-fold in 
RIP-1 expression levels after incubation with [Au(C≡C-2-NC5H4)(PTA)] (Figure 4B), 
which confirms the role of this protein in cell death.  
Further flow cytometry cell death studies revealed that co-incubation of our gold 
complex and Nec-1 resulted in a decrease of cells undergoing late apoptosis in addition 
of an increase in early apoptotic cells (Supplementaty Material Figure S11). This result 
indicates that necroptosis disruption might favor apoptotic cell death.  
Figure 4. Caco-2/TC7 cell death analysis after 24 incubation with A) DMSO (mock-treated
cells) and B) [Au(C≡C-2-NC5H4)(PTA)] (3.8 µM). 
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The balanced character between lipophility and hydrophilicity of our gold complex 
allows its entrance in mitochondria. The luminescent properties of [Au(C≡C-2-
NC5H4)(PTA)] [33] let us to perform co-localization studies using the mitochondrial 
dye Mitotracker® Deep Red. Microscopy fluorescence assay showed a high co-
Figure 5. A) Effect of TNFR1 analog (5 μM, 1 h) against [Au(C≡C-2-NC5H4)(PTA)] (3.8 μM). *p<0.05 
respect to mock-treated cells. #p<0.05 respect to treatment with [Au(C≡C-2-NC5H4)(PTA)] (3.8 μM). B) 
Effect of SN50 (1 μM, 1 h) against [Au(C≡C-2-NC5H4)(PTA)] (3.8 μM). *p<0.05 respect to mock-
treated cells. #p<0.05 respect to treatment with [Au(C≡C-2-NC5H4)(PTA)] (3.8 μM). 
Figure 4. A) Effect of Nec-1 (50 μM, 1h) against [Au(C≡C-2-NC5H4)(PTA)] (3.8 μM). *p<0.05 respect 
to mock-treated cells. #p<0.05 respect to treatment with [Au(C≡C-2-NC5H4)(PTA)] (3.8 μM). B) RIP-1 
expression levels after 24 h treatment with DMSO (panel A) or [Au(C≡C-2-NC5H4)(PTA)] (3.8 μM). 
(panel B).  
A B 
A B 
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localization between the gold complex and this organelle via the Van Steensel co-
localization test (Figure 6.1). The accumulation of [Au(C≡C-2-NC5H4)(PTA)] in 
mitochondria disrupts its normal function, inducing a loss of mitochondrial membrane 
potential (Δψm) as can be observed in Figure 6.2 As a result, an imbalance in normal 
ROS generation is produced. Total oxidative stress was investigated using the 
fluorogenic probe CellROX® Deep Red Reagent. The cell-permeant dye is non-
fluorescent while in a reduced state, but exhibits bright fluorescence upon oxidation by 
ROS, so the fluorescence signal correlates with ROS levels. Fluorescence signal was 
significant higher after [Au(C≡C-2-NC5H4)(PTA)] treatment, revealing a great amount 
of oxidative stress induced (Figure 7.1). Since mitochondrial and extramitochondrial 
abnormal ROS generation has been related to necroptotic cell death without caspase 
activation [23] and some authors argue that RIP-1 might directly disrupt normal 
mitochondrial function and therefore contribute to the increase of ROS levels, [52] we 
measured H2O2 levels after [Au(C≡C-2-NC5H4)(PTA)] in presence or absence of Nec-1. 
Pre-incubation with Nec-1 resulted in no changes in H2O2 levels, similar to mock-
treated cells or cells treated with the ROS inhibitor N-acetyl-cysteine (NAC) (Figure 
7.2). Abnormally increased ROS levels are usually involved in apoptosis, high amounts 
of H2O2 have been found able to inhibit caspases and as a result trigger necrotic death 
[53, 54]. Furthermore, MTT assay revealed the protective effect of NAC against 
[Au(C≡C-2-NC5H4)(PTA)] (Figure S12), which finally probed the role of ROS in cell 
death.  
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Figure 6.2 Representative histograms of effects on mitochondrial membrane potential after 24 h 
treatment with DMSO (panel A) or [Au(C≡C-2-NC5H4)(PTA)] (10 µM) (B). 
Figure 6.1 A) Co-localization of [Au(C≡C-2-NC5H4)(PTA)] 3.8 µM and mitochondria after 24 
h incubation. B) Co-localization graph of [Au(C≡C-2-NC5H4)(PTA)] and mitochondria as 
determined via Van Steensel co-localization test of the images show in A.  
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[Au(C≡C-2-NC5H4)(PTA)] shows how small changes in structure lead to different 
properties and behavior against cancerous cells. Thus, this complex links BSA much 
stronger than the related [Au(C≡C-C6H5)(PTA)] (Kb = 2.46·10
8
 vs 7.2·10
4 
M
-1
) [20] and
induces necroptotic cell death in CRC cells with an increase in ROS production and a 
minimal inhibition of TrxR and without effect on glutathione reductase activity 
(Supplementary Material, Table T2 and T3). However, the counterpart [Au(C≡C-
C6H5)(PTA)] triggers mitochondrial apoptotic by inhibiting TrxR and consequently 
increasing ROS levels. The main difference between both derivatives resides on the 
heteroatom N in the alkynyl unit. This pyridyl unit could favor additional interactions 
between neighboring molecules, as has been observed previously in the analogous 4-
pyridylethynyl derivative with PTA [55]. The reported complex, which unlike our 
Figure 7.1 ROS generation after incubation with A) DMSO or B) [Au(C≡C-2-NC5H4)(PTA)] 
(3.8 μM)  for 80 min. 
Figure 7.2 H2O2 generation after incubation with [Au(C≡C-2-NC5H4)(PTA)] (3.8 µM) for 80 
min with or without pre-incubation with Nec-1 (50 µM, 1h) or NAC (3 mM, 1h). *p<0.05 
respect to treatment with [Au(C≡C-2-NC5H4)(PTA)] (3.8 μM). 
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derivative is very soluble in water, shows the formation of gel structure in water 
solution, giving rise to long fibers, thanks to π- π interactions between the pyridyl units. 
The occurrence of similar π- π interactions in our complex between the PTA molecule 
and the pyridyl unit is less probable, since any trace data could be retrieved from the 
corresponding 2D-NOESY spectrum, (Figure S9). Nevertheless, the position of the N 
atom in the pyridyl ring could support additional N-metal interactions between two 
molecules besides metal-triple bond contacts, as occurred in [Au(C≡C-2-NC5H4)(PPh3)] 
[56]. 
Effect of [Au(C≡C-2-NC5H4)(PTA)] on Caco-2 spheroids (3D model). We tested 
increasing concentrations of [Au(C≡C-2-NC5H4)(PTA)] on Caco-2 spheroids. The 
morphology of spheroids may vary attending to different factors which include the 
inherent nature of cells or cell culture conditions. According to Nath et al [28], Caco-2 
spheroids showed a “grape-like” morphology. 
We studied cell viability by means of a double staining Hoechst 33342(blue)-PI(red) 
and fluorescence microscopy. The increase in red fluorescence in response to gold 
complex concentrations (Figure 8) correlated with a gradual decrease in survival ratio, 
since PI only stains dead cells. In addition, nuclei swelling indicated with white arrows 
is consistent with cells undergoing necroptotic cell death, as mentioned in Figure 3.2.   
 Viability studies revealed that our gold compound induced cell death in a tumor-like 
environment (Figure 8), which suggests that its anticancer properties may remain 
unchanged into a living organism. It is remarkable that, although in 3D model the 
decrease in viability observed was lower than the found in 2D for the same gold 
complex concentrations, cell properties differ greatly between each experiment as has 
been widely discussed previously. Consequently, these results support our initial 
hypothesis that this gold(I) complex has a considerable antitumor potential and it is not 
ruled out its chemotherapeutic use in the future.  
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Figure 8. Fluorescence microscopy images of Caco-2 spheroids in response to 24 h incubation [Au(C≡C-2-NC5H4)(PTA)] 
A) 0 µM B) 3 µM C) 4µM and D) 5 µM. Nuclei swelling are also highlighted (white arrows). 
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CONCLUSSIONS 
The antitumor potential of a previously characterized alkynyl gold(I) complex 
([Au(C≡C-2-NC5H4)(PTA)]) has been evaluated on colorectal adenocarcinoma Caco-2 
cell line. A strong interaction between a blood plasma protein (BSA) and the gold 
complex has been calculated, which makes the complex suitable for transportation by 
the protein through blood and release to the target and suitable for chemotherapy 
treatments. Its balanced character between lipophilicity and hydrophilicity allows it 
going across cell membranes. Therefore, ([Au(C≡C-2-NC5H4)(PTA)]) goes through 
mitochondrial membrane and alters its function, inducing an increase in ROS levels. 
The abnormal production of ROS triggers TNF-induced necroptosis dependent of RIP-1 
activation and NF-κB signaling. Furthermore, we have proved that this compound 
maintains its therapeutic properties in a tumor-like environment using 3D model 
spheroids. In addition, we have demonstrated how small changes in the structure, 
namely an additional N atom in the alkyne skeleton, lead to different properties and 
behavior against cancerous cells. The findings of the present work provide a new insight 
into the use of gold as a substitute for platinum in chemotherapy, since [Au(C≡C-
C5H4)(PTA)] has proved its efficacy against tumors at lower concentrations than 
cisplatin. Moreover, since its mechanism of action is via necroptosis, our complex could 
be used in the treatment of tumors resistant to apoptosis. To our knowledge, this is the 
first report of an alkynyl gold(I) complex able to induce necroptosis in cancer cells.  
ABBREVIATIONS 
TrxR: thioredoxin reductase, ROS: Reactive oxygen species, CRC: colorectal cancer, 
RIP-1: receptor-interacting protein 1, MLKL: mixed lineage kinase domain-like, TNF: 
tumor necrosis factor, DMEM: Dulbecco’s modified Eagles medium, FBS: fetal bovine 
serum, MTT: 3-(4,5-dimethyl-2-thiazoyl)-2,5-diphenyltetrazolium bromide, DMSO: 
dimethyl sulfoxide, PI: propidium iodide, DCF: dichlorofluorescein, DilC1: 1,1’,3,3,3’-
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hexamethylindodicarbo-cyanine iodide, DTNB: 5,5-dithio-bis-(2-nitrobenzoic acid), 
PS: phosphatidylserine, Nec-1: necrostatin-1 
NAC: N-acetyl-cysteine, Δψm: mitochondrial membrane potential 
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HIGHLIGHTS 
- Gold(I) complex [Au(C≡C-2-NC5H4)(PTA)] induces necroptosis on Caco-2 cells.  
- The complex enters the mitochondria, alters its function and produces ROS 
increase. 
- Necroptosis depends on ROS increase, TNF-, RIP-1 activation and NF-κB 
signaling.  
- [Au(C≡C-2-NC5H4)(PTA)] induces cell death on 2D and 3D colorectal carcinoma 
model  
- This is the first evidence of gold compound able to overcome apoptosis 
resistance. 
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